2010
Outcomes following local therapy for early-stage breast cancer in non-trial populations
Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Research And Treatment 2010, 125: 803-813. PMID: 20376555, PMCID: PMC2924956, DOI: 10.1007/s10549-010-0865-4.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryEarly-stage breast cancerClinical trialsBreast cancerEarly-stage breast cancer patientsPrimary breast cancer therapyPrimary breast cancer treatmentEnd Results cancer registryNon-trial populationBreast cancer patientsPopulation-based dataBreast cancer treatmentBreast cancer therapyNon-selected populationPropensity score analysisMedicare administrative dataMore mastectomiesPrimary therapyLocal therapySurveillance EpidemiologyAdjusted survivalCancer RegistryCancer patientsHospital characteristicsMastectomy
2006
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer. Cancer 2006, 106: 2576-2582. PMID: 16703595, DOI: 10.1002/cncr.21919.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCross-Over StudiesDecision Support TechniquesDisease-Free SurvivalDrug Administration ScheduleFemaleHumansMarkov ChainsMiddle AgedModels, StatisticalModels, TheoreticalNeoplasm StagingOdds RatioPostmenopauseRandomized Controlled Trials as TopicReceptors, ProgesteroneTamoxifenTime FactorsTreatment OutcomeConceptsDisease-free survivalAromatase inhibitorsProgesterone receptorEstrogen receptorOptimal adjuvant endocrine therapyEarly-stage breast cancerAdjuvant endocrine therapyNode-positive groupProgesterone receptor statusRandomized clinical trialsSequential treatmentBreast cancer tumorsAI monotherapyAI therapyBiologic subsetsDFS ratesAdjuvant therapyEndocrine therapyPostmenopausal patientsPostmenopausal womenSequential therapyUpfront treatmentLymph nodesReceptor statusPR expression